| scholarly article | Q13442814 |
| P50 | author | Thor Ueland | Q12006168 |
| Stein Ørn | Q19390407 | ||
| Thor Edvardsen | Q38544662 | ||
| Kenneth Dickstein | Q43248428 | ||
| Pål Aukrust | Q47504859 | ||
| Jan Kristian Damås | Q47504873 | ||
| Tom Eirik Mollnes | Q73118485 | ||
| P2093 | author name string | Cord Manhenke | |
| P2860 | cites work | Detection of acutely impaired microvascular reperfusion after infarct angioplasty with magnetic resonance imaging | Q28168468 |
| Increased C-reactive protein level after coronary stent implantation in patients with stable coronary artery disease | Q28194989 | ||
| Interleukin-7-mediated inflammation in unstable angina: possible role of chemokines and platelets | Q28195974 | ||
| C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction | Q33883883 | ||
| Inflammatory cytokines and postmyocardial infarction remodeling | Q34329136 | ||
| Comparison of C-reactive protein and terminal complement complex in patients with unstable angina pectoris versus stable angina pectoris | Q40647004 | ||
| Comparison of myocardial infarct size assessed with contrast-enhanced magnetic resonance imaging and left ventricular function and volumes to predict mortality in patients with healed myocardial infarction | Q43660266 | ||
| Relationship between size of myocardial infarctions assessed by delayed contrast-enhanced MRI after primary PCI, biochemical markers, and time to intervention | Q45152229 | ||
| Effect of left ventricular scar size, location, and transmurality on left ventricular remodeling with healed myocardial infarction. | Q47292536 | ||
| Gadolinium delayed enhancement cardiovascular magnetic resonance correlates with clinical measures of myocardial infarction | Q47355270 | ||
| Accuracy of Contrast-Enhanced Magnetic Resonance Imaging in Predicting Improvement of Regional Myocardial Function in Patients After Acute Myocardial Infarction | Q57736613 | ||
| Plasma levels of C-reactive protein after coronary stent implantation | Q58071743 | ||
| P433 | issue | 10 | |
| P921 | main subject | myocardial infarction | Q12152 |
| microvessel | Q6840468 | ||
| P304 | page(s) | 1180-1186 | |
| P577 | publication date | 2009-03-19 | |
| P1433 | published in | European Heart Journal | Q2286839 |
| P1476 | title | C-reactive protein, infarct size, microvascular obstruction, and left-ventricular remodelling following acute myocardial infarction | |
| P478 | volume | 30 |
| Q48500144 | Acute heart failure following myocardial infarction: complement activation correlates with the severity of heart failure in patients developing cardiogenic shock |
| Q90136969 | Antibiotic prescribing in general medical and surgical specialties: a prospective cohort study |
| Q54345381 | Antioxidant N-acetyl cysteine reverses cigarette smoke-induced myocardial infarction by inhibiting inflammation and oxidative stress in a rat model. |
| Q51184443 | Association between local interleukin-6 levels and slow flow/microvascular dysfunction. |
| Q61942654 | Bioactive Sphingolipids, Complement Cascade, and Free Hemoglobin Levels in Stable Coronary Artery Disease and Acute Myocardial Infarction |
| Q54946647 | C-Reactive Protein in Atherothrombosis and Angiogenesis. |
| Q35859423 | C-Reactive protein reactions to glucose-insulin-potassium infusion and relations to infarct size in patients with acute coronary syndromes |
| Q59133072 | C-reactive protein during and after myocardial infarction in relation to cardiac injury and left ventricular function at follow-up |
| Q96225069 | C-reactive protein: a promising biomarker for poor prognosis in COVID-19 infection |
| Q37076069 | Circulating Levels of IL-6 Receptor and gp130 and Long-Term Clinical Outcomes in ST-Elevation Myocardial Infarction |
| Q54377887 | Complement factor concentrations in patients with acute myocardial infarction: time course and ability to predict left ventricular dysfunction. |
| Q33816471 | Creating a Biomarker Panel for Early Detection of Chemotherapy Related Cardiac Dysfunction in Breast Cancer Patients |
| Q50668373 | Does longitudinal strain predict left ventricular remodeling after myocardial infarction? |
| Q45797174 | Early kinetics of serum Interleukine-17A and infarct size in patients with reperfused acute ST-elevated myocardial infarction. |
| Q36816882 | Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study]. |
| Q93198231 | Electroacupuncture Ameliorates Acute Myocardial Ischemia: A Potential Role of the Locus Coeruleus |
| Q93007285 | Enhanced Inflammation is a Marker for Risk of Post-Infarct Ventricular Dysfunction and Heart Failure |
| Q37907327 | Established and novel biomarkers in ST-elevation myocardial infarction |
| Q49404278 | Factors associated with the no-reflow phenomenon following percutaneous intervention of saphenous vein coronary bypass grafts |
| Q86227598 | High sensitive C-reactive protein and the risk of acute kidney injury among ST elevation myocardial infarction patients undergoing primary percutaneous intervention |
| Q38598201 | IL-6 signalling in patients with acute ST-elevation myocardial infarction |
| Q48714746 | Increased interleukin-1β levels are associated with left ventricular hypertrophy and remodelling following acute ST segment elevation myocardial infarction treated by primary percutaneous coronary intervention |
| Q50276697 | Increased red cell distribution width predicts occlusion of the infarct-related artery in STEMI. |
| Q34983608 | Increased systemic and local interleukin 9 levels in patients with carotid and coronary atherosclerosis |
| Q38355385 | Inflammatory markers in ST-elevation acute myocardial infarction |
| Q89980177 | Interleukin-1 Blockade Inhibits the Acute Inflammatory Response in Patients With ST-Segment-Elevation Myocardial Infarction |
| Q38703283 | Is cardiac magnetic resonance necessary for prediction of left ventricular remodeling in patients with reperfused ST-segment elevation myocardial infarction? |
| Q54277415 | Left ventricular remodelling after acute myocardial infarction: impact of clinical, echocardiographic parameters and polymorphism of angiotensinogen gene. |
| Q34777497 | Leukocyte activity in patients with ST-segment elevation acute myocardial infarction treated with anakinra |
| Q37328708 | Macrophage migration inhibitory factor for the early prediction of infarct size. |
| Q82603176 | Markers of oxidative stress after ablation of atrial fibrillation are associated with inflammation, delivered radiofrequency energy and early recurrence of atrial fibrillation |
| Q54621218 | Molecular and cellular mechanisms involved in cardiac remodeling after acute myocardial infarction. |
| Q34533036 | Myocardial connective tissue growth factor (CCN2/CTGF) attenuates left ventricular remodeling after myocardial infarction |
| Q57035429 | Neprilysin levels at the acute phase of ST-elevation myocardial infarction |
| Q38414861 | Non-contrast cardiac CT immediately after percutaneous coronary intervention: does it predict the risk of left ventricular remodeling in patients with ST-elevation myocardial infarction? |
| Q37240620 | Plasma Macrophage Migration Inhibitor Factor Is Elevated in Response to Myocardial Ischemia |
| Q84934992 | Plasma fibrinogen levels and restenosis after primary percutaneous coronary intervention |
| Q91622756 | Prognostic implications of post-percutaneous coronary intervention neutrophil-to-lymphocyte ratio on infarct size and clinical outcomes in patients with acute myocardial infarction |
| Q58597439 | Prognostic significance and dynamic change of plasma macrophage migration inhibitory factor in patients with acute ST-elevation myocardial infarction |
| Q49069370 | Rationale and design of the TETHYS trial: the effects of methotrexate therapy on myocardial infarction with ST-segment elevation |
| Q99633698 | Short-term effect of low-dose colchicine on inflammatory biomarkers, lipids, blood count and renal function in chronic coronary artery disease and elevated high-sensitivity C-reactive protein |
| Q98465905 | Surface modification of small intestine submucosa in tissue engineering |
| Q36141760 | Systemic Atherosclerotic Inflammation Following Acute Myocardial Infarction: Myocardial Infarction Begets Myocardial Infarction |
| Q35905573 | The Relationship among N-Terminal Pro-B-Type Natriuretic Peptide, High-Sensitivity C-Reactive Protein and Infarct Size in Patients with Acute ST-Elevation Myocardial Infarction |
| Q37622476 | The impact of C reactive protein on global cardiovascular risk on patients with coronary artery disease |
| Q42379231 | Transplantation of Isl1+ cardiac progenitor cells in small intestinal submucosa improves infarcted heart function. |
| Q36031419 | Usefulness of C-reactive protein as a marker of early post-infarct left ventricular systolic dysfunction |
| Q47133297 | Usefulness of the delta neutrophil index to predict 30-day mortality in patients with ST segment elevation myocardial infarction. |
| Q101121110 | Using proximity extension proteomics assay to identify biomarkers associated with infarct size and ejection fraction after ST-elevation myocardial infarction |
| Q36225152 | Value of C-reactive protein in predicting left ventricular remodelling in patients with a first ST-segment elevation myocardial infarction |
Search more.